Comparisons Tirzepatide vs Survodutide

Tirzepatide vs Survodutide

Side-by-side comparison of weight loss results, pricing, side effects, and clinical data.

Tirzepatide

~22%

Survodutide

~19%

Head-to-Head Comparison

Metric
TirzepatideMounjaro / Zepbound
SurvodutideNot yet approved (Boehringer Ingelheim)
Drug Class
GLP-1/GIP dual agonist
GLP-1/Glucagon dual agonist
Administration
Weekly injection
Weekly injection
Dosing
Once weekly
Once weekly
Avg. Weight Loss
~22%
~19%
Half-Life
~5 days
~7 days
Compounded Cost
$150-450/mo (compounded)
Not yet available
Brand Cost
$1,000-1,200/mo
Not yet available
FDA Approved
2022
—
Key Trial
SURMOUNT-1 (22.5% weight loss)
Phase 2 (up to 18.7% weight loss at 46 weeks)

Side Effects Comparison

Tirzepatide

  • Nausea
  • Diarrhea
  • Decreased appetite

Survodutide

  • Nausea
  • Diarrhea
  • Vomiting

Pros & Cons

Tirzepatide

Pros

  • +FDA-approved and widely available
  • +Extensive Phase 3 data
  • +Proven dual mechanism

Cons

  • -Does not target glucagon receptor
  • -GIP component less studied long-term

Survodutide

Pros

  • +GLP-1 + glucagon mechanism (different from tirzepatide)
  • +Strong liver fat reduction
  • +Promising MASH/NASH data

Cons

  • -Not yet approved
  • -Slightly less weight loss than tirzepatide
  • -Limited long-term data

The Verdict

Tirzepatide (GLP-1/GIP) is available now and achieves ~22% weight loss. Survodutide (GLP-1/glucagon) shows ~19% in Phase 2 with a different mechanism that may be especially beneficial for liver disease (MASH). They target different secondary receptors, so the best choice may depend on the patient's full metabolic profile.

No direct comparison. Different mechanisms: tirzepatide targets GIP while survodutide targets glucagon.

Which Is Right for You?

Choose Tirzepatide if...

Patients wanting the most effective available weight loss medication today

Choose Survodutide if...

Future option, especially for patients with fatty liver disease (MASH/NASH)

Frequently Asked Questions

What is survodutide?

Survodutide is a dual GLP-1/glucagon receptor agonist being developed by Boehringer Ingelheim. Unlike tirzepatide (GLP-1/GIP), it pairs GLP-1 with glucagon, which may boost energy expenditure and improve liver fat.

When will survodutide be available?

Survodutide is in Phase 3 trials for obesity and MASH (fatty liver disease). Approval could come in 2026-2027 if trials succeed.

How does survodutide differ from tirzepatide?

Both use GLP-1, but tirzepatide adds GIP (improves insulin sensitivity) while survodutide adds glucagon (increases energy expenditure and reduces liver fat). They represent different approaches to dual-receptor therapy.

Find a provider prescribing Tirzepatide or Survodutide

Compare pricing, reviews, and availability across 18,000+ GLP-1 providers nationwide.

Search Providers →

View all GLP-1 comparisons

Compare every major GLP-1 medication side by side. Weight loss data, cost analysis, and clinical trial results.

All Comparisons →